Nispomeben (NRD135S.E1)
Small molecule
Evidence outlook · lead readout
EN21-01 (NCT05480228) · Painful Diabetic Neuropathy
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
EN21-01 (NCT05480228): The trial randomized 127 participants to NRD135S.E1 or placebo and used double-blind masking. Its primary pain endpoint was a clinical patient-reported measure.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02345291 NCT02345291 · Diabetic Peripheral Neuropathic Pain The study was randomized and triple-masked, with three NRD135S.E1 dose groups compared with placebo, and enrolled 88 participants. Its primary clinical endpoint was change in average daily pain intensity on an 11-point pain scale. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT02345291 | 2 | • Change from the baseline week to Week 3 in the weekly average daily pain intensity as measured on an 11-point numerical pain scale (NPS) (three weeks) 2016-07 | Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). | Partial signal | link ↗ |
View 1 more trial
EN21-01 NCT05480228 · Painful Diabetic Neuropathy The trial randomized 127 participants to NRD135S.E1 or placebo and used double-blind masking. Its primary pain endpoint was a clinical patient-reported measure. Registry: NCT05480228 | 2 | To demonstrate that NRD135S.E1 80 mg daily is superior to placebo in relieving neuropathic pain associated with PDPN, after 13 weeks' treatment.; The frequency (i.e. number of participants) with treatment emergent adverse events (TEAEs) reported in the time period defined by first administration of IP until 7 days after the last dose of IP. (13 weeks) 2025-08-31 | Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Diabetic Peripheral Neuropathic Pain: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nispomeben (NRD135S.E1): this drug | Phase 2 | Small molecule | — | Partial signal | NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed | |
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | Reliable signal | NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92) NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%. | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | Partial signal | NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14) NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Partial signal | No reviewed efficacy summary in this indication | |
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | Reliable signal | NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43) NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41) | |
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | Reliable signal | NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001) | |
| Mirogabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | Partial signal | NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301 NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6) | |
| Suzetrigine (Journavx) | Phase 3 | Small molecule | Voltage-gated sodium channel NaV1.8 | Partial signal | NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70) | |
| HL-1186 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | Partial signal | No reviewed efficacy summary in this indication | |
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | Partial signal | NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36) | |
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic M1 receptor (antagonist) | Partial signal | Featured results are safety only in this race | |
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | not yet graded | No reviewed efficacy summary in this indication | |
| AJH-2947 | Phase 1(overall) | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| HRS-2129 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| QR-333 | Discontinued | Botanical | — | not yet graded | No reviewed efficacy summary in this indication | |
| Tanezumab | Discontinued | Monoclonal antibody | Nerve growth factor (NGF) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.